Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
AXGN · against 337 other Healthcare companies of similar size
Ranked #253 of 338 · scores higher than 4% of peers
Bars: peers in each 10-point band of the valuation score86 peers with a valuation score of 0–9, including AXGN · Click a bar to see the companies
Mainly because of its EBITDA yield and earnings yield, which are weaker than most Healthcare peers.
| Metric | AXGN | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 330 reported | -1.4% | 2.3% | 31% | 30% | |
| EBITDA yieldHigher is better · 334 reported | -0.2% | 4.6% | 27% | 50% | |
| Free cash flow yieldHigher is better · 178 reported | 0.2% | -0.1% | 51% | 20% | |
| Book yieldHigher is better · 330 reported | 9.6% | 30.4% | 14% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 12.9B HKD (≈$1.7B) | 99 | 83 | |
| 1 | 226.3B JPY (≈$1.5B) | 99 | 77 | |
| 1 | 37.3B HKD (≈$4.8B) | 99 | 90 | |
| 253 | 4.1B USD | 8 | 39 | |
| 253 | 1.9B USD | 8 | 49 | |
| 253 | 1.5B USD | 8 | 26 | |
| 253 | 3.7B USD | 8 | 31 | |
| 253 | 2.9B USD | 8 | 44 | |
| 253 | 2.2B USD | 8 | 32 | |
| 253 | 2.7B USD | 8 | 50 | |
| 253 | 1.7B USD | 8 | 30 | |
| 253 | 2.4B USD | 8 | 6 |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score